新しいDPYD変異の文脈におけるカペシタビン誘発の致死性の疑い
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。診断されていないディヒドロピリミジン脱水素酶 (DPYD) 欠乏症による化学療法合併症により死亡し,現在のフッ素ピリミジン治療の安全性に関するDPYD遺伝子検査の限界を強調した.
科学分野
- 腫瘍学
- ファルマゲノミクス
- 臨床毒理学
背景
- フロロピリミジン化学療法は,様々な癌の治療における基石です.
- ディヒドロピリミジン脱水素酶 (DPYD) の酵素活性は,フッ素ピリミジン代謝に極めて重要です.
- DPYD欠乏症は,重症で生命を脅かす毒性につながる可能性があります.
研究 の 目的
- DPYD欠乏症の疑いのある患者の重度のフッ素ピリミジン毒性の致死症例を報告する.
- 標準的なDPYD遺伝子型決定の限界を強調し,すべての欠陥を引き起こす変種を検出する.
- フロロピリミジン投与の注意と 毒性の総合的なモニタリングの必要性を強調する
主な方法
- 70代前半の男性で 補助化学療法を受けている
- 治療前の標準的なDPYD遺伝子型検査の結果のレビュー
- 胃腸に重度の毒性,腸不全,患者の死亡の臨床観察
主要な成果
- 患者は重度の胃腸毒性を発症し,腸の不全と死亡に至った.
- 標準的なDPYD遺伝子型検査結果は,化学療法前の正常でした.
- 結果は未診断のDPYD欠乏症を示唆し,未検出の変異によって引き起こされる可能性がある.
結論
- 現在のDPYDゲノタイプは,機能的に有意なDPYD変異をすべて特定できない可能性があります.
- フロロピリミジン治療中の予期せぬ重度の毒性は,注意深く再評価し,DPYD欠乏症を考慮することを要求する.
- 患者のモニタリングと潜在的なDPYD欠乏に対する包括的なアプローチは,フッ素ピリミディンの安全な使用に不可欠です.
関連する概念動画
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...